A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).

被引：0
|
作者：
Pan, Chong-xian
Lara, Primo
Evans, Christopher P.
Parikh, Mamta
White, Ralph de Vere
Dall'era, Marc
Liu, Chengfei
Robles, Daniel
Gao, Allen
机构：
[1] Univ Calif Davis Comprehens Canc Ctr, Sacramento, CA USA
[2] Univ Calif Davis, Sacramento, CA USA
[3] Pandomedx Inc, Davis, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.TPS394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS394
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
    Serritella, Anthony, V
    Shevrin, Daniel
    Heath, Elisabeth, I
    Wade, James L.
    Martinez, Elia
    Anderson, Amanda
    Schonhoft, Joseph
    Chu, Yen-Lin
    Karrison, Theodore
    Stadler, Walter M.
    Szmulewitz, Russell Z.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1549 - 1559
  • [22] Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
    Penson, David F.
    Armstrong, Andrew J.
    Concepcion, Raoul
    Agarwal, Neeraj
    Olsson, Carl
    Karsh, Lawrence
    Dunshee, Curtis
    Wang, Fong
    Wu, Kenneth
    Krivoshik, Andrew
    Phung, De
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) : 2098 - +
  • [23] Clinical investigation of enzalutamide for nonmetastatic castration-resistant prostate cancer (M0CRPC)
    Mukouyama, Hideki
    Nakasone, Kei
    Yoshimi, Naoki
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
    Sweeney, Christopher J.
    Percent, Ivor J.
    Babu, Sunil
    Cultrera, Jennifer L.
    Mehlhaff, Bryan A.
    Goodman, Oscar B.
    Morris, David S.
    Schnadig, Ian D.
    Albany, Costantine
    Shore, Neal D.
    Sieber, Paul R.
    Guba, Susan C.
    Zhang, Wei
    Wacheck, Volker
    Donoho, Gregory P.
    Szpurka, Anna M.
    Callies, Sophie
    Lin, Boris Kin
    Bendell, Johanna C.
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2237 - 2247
  • [25] Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    Powles, Thomas
    Yuen, Kobe C.
    Gillessen, Silke
    Kadel, Edward E.
    Rathkopf, Dana
    Matsubara, Nobuaki
    Drake, Charles G.
    Fizazi, Karim
    Piulats, Josep M.
    Wysocki, Piotr J.
    Buchschacher, Gary L., Jr.
    Alekseev, Boris
    Mellado, Begona
    Karaszewska, Boguslawa
    Doss, Jennifer F.
    Rasuo, Grozdana
    Datye, Asim
    Mariathasan, Sanjeev
    Williams, Patrick
    Sweeney, Christopher J.
    NATURE MEDICINE, 2022, 28 (01) : 144 - +
  • [26] Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    Thomas Powles
    Kobe C. Yuen
    Silke Gillessen
    Edward E. Kadel
    Dana Rathkopf
    Nobuaki Matsubara
    Charles G. Drake
    Karim Fizazi
    Josep M. Piulats
    Piotr J. Wysocki
    Gary L. Buchschacher
    Boris Alekseev
    Begoña Mellado
    Bogusława Karaszewska
    Jennifer F. Doss
    Grozdana Rasuo
    Asim Datye
    Sanjeev Mariathasan
    Patrick Williams
    Christopher J. Sweeney
    Nature Medicine, 2022, 28 : 144 - 153
  • [27] Pilot trial of physical and cognitive changes related to fall risk in enzalutamide patients with castration-resistant prostate cancer (CRPC).
    Rodriguez, Victor
    Cameron, Michelle
    Winters-Stone, Kerri M.
    Beer, Tomasz M.
    Alumkal, Joshi J.
    Cetnar, Jeremy Paul
    Thawani, Rajat
    Amery, Taylor
    Vuky, Jacqueline
    Bailey, Shawna
    Graff, Julie N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17018 - E17018
  • [28] Castration-resistant prostate cancer (CRPC) [Kastrationsrefraktäres prostatakarzinom (CRPC)]
    Loidl W.
    Luger F.
    Roosen A.
    Der Urologe, 2014, 53 (3): : 391 - 401
  • [29] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
    Chandrasekar, Thenappan
    Yang, Joy C.
    Gao, Allen C.
    Evans, Christopher P.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) : 365 - 380
  • [30] Everolimus plus bicalutamide in men with castration-resistant prostate cancer (CRPC): Final results of a phase II trial.
    Pan, Chong-xian
    Chow, Helen
    Ghosh, Paramita
    White, Ralph deVere
    Evans, Christopher P.
    Dall'Era, Marc A.
    Yap, Stanley A.
    Li, Judy
    Beckett, Laurel A.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345